Shares of Intelgenx Technologies (CVE IGX) opened at C$1.06 on Monday. The company has a market capitalization of $68.07, a P/E ratio of -35.33 and a beta of -0.04. Intelgenx Technologies has a 12-month low of C$0.78 and a 12-month high of C$1.39.
Intelgenx Technologies (CVE:IGX) last released its quarterly earnings results on Thursday, November 9th. The company reported C($0.01) EPS for the quarter, hitting the Zacks’ consensus estimate of C($0.01).
IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The companys products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimers disease.
Receive News & Ratings for Intelgenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelgenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.